Milestone Scientific Stock Jumps 9% on Narrower Loss

Shares of Milestone Scientific (NYSE:MLSS) surged over 9% on May 14, 2026, following the release of its first-quarter financial results. According to a report from investing.com, the medical technology company announced a narrower net loss compared to the prior year, signaling improved operational efficiency and revenue growth. The positive market reaction pushed the stock to its highest level in three months, reflecting renewed investor confidence in the company's commercialization strategy for its proprietary drug delivery instruments.

What Drove Milestone's Reduced Net Loss?

Milestone Scientific's improved first-quarter performance was anchored by both revenue growth and disciplined cost management. The company reported quarterly revenue of $3.1 million, a 24% increase from the $2.5 million recorded in the same period of the previous year. This growth was primarily driven by higher sales volumes of its CompuFlo Epidural and CathCheck disposables.

The company posted a net loss of $1.8 million, or $0.02 per share, for the quarter. This represents a significant improvement from the $2.4 million net loss, or $0.03 per share, reported in the first quarter of 2025. Management attributed the narrower loss to higher gross margins, which expanded by 250 basis points, and a slight reduction in selling, general, and administrative (SG&A) expenses as a percentage of revenue.

How Does This Affect the CompuFlo System's Outlook?

The strong financial results provide a positive backdrop for the continued rollout of the CompuFlo Epidural system. Increased revenue and a reduced cash burn rate strengthen the company's ability to fund its sales and marketing initiatives aimed at expanding its hospital network. In the first quarter, Milestone reported the sale of 22,000 disposable units, a 30% increase year-over-year.

This momentum is critical for penetrating the anesthesiology market, where the CompuFlo system offers a technological advantage over traditional epidural techniques. The instrument provides real-time pressure feedback to help clinicians accurately locate the epidural space, potentially reducing complications. The improved financial footing allows Milestone to better support clinical trials and marketing efforts to drive further adoption. For more on medical device markets, see Fazen Markets' healthcare sector analysis.

What Is Milestone's Path to Profitability?

Despite the narrower loss, Milestone Scientific has not yet reached profitability. The company's path forward depends on its ability to scale revenue at a faster pace than its operating expenses. The primary challenge remains the long sales cycles and extensive validation processes required to onboard new hospitals and surgical centers. This is a common hurdle for companies in the medical technology space.

As an acknowledged risk, the company's cash burn, while reduced, still stands at approximately $1.6 million for the quarter. Milestone's success is contingent upon maintaining its sales growth trajectory to reach cash-flow breakeven before its current capital reserves are depleted. Competition from established medical device manufacturers and the inherent resistance to change in clinical practice are significant headwinds the company must continue to manage.

How Are Investors Valuing MLSS Stock Now?

The 9% stock price increase reflects a shift in investor sentiment, with the market rewarding the company's progress toward a more sustainable business model. Following the surge, Milestone Scientific's market capitalization rose to approximately $85 million. Trading volume on the day of the announcement exceeded 700,000 shares, nearly four times the 90-day average daily volume of 180,000 shares.

Analysts are now watching to see if the company can maintain this momentum in the coming quarters. The valuation remains that of a growth-stage company, where future potential is prized over current earnings. The stock's performance in the second half of 2026 will likely depend on continued growth in disposable sales and the successful conversion of its pipeline of new hospital clients.

Q: What is Milestone Scientific's primary product?

A: Milestone Scientific's flagship product is the CompuFlo Epidural System. It is a computer-controlled injection technology that helps anesthesiologists correctly identify the epidural space for placing a catheter. By providing objective, real-time pressure readings, the system is designed to improve the safety and success rate of epidural procedures compared to the traditional loss-of-resistance technique, which relies on the clinician's subjective feel.

Q: Has Milestone Scientific ever been profitable?

A: No, as of its latest reporting period, Milestone Scientific has not yet achieved a full quarter or year of profitability. The company is currently in a high-growth phase, investing heavily in research and development, sales, and marketing to establish its technology and gain market share. Its financial strategy is focused on scaling revenue to a point where it can sustainably cover its operational costs and eventually generate profit.

Q: What is CathCheck and how does it relate to CompuFlo?

A: CathCheck is a feature of the CompuFlo Epidural System that serves as a verification tool. After an epidural catheter has been placed, CathCheck allows the clinician to confirm that it has not been inadvertently moved into an intravascular (in a blood vessel) location. This patented technology provides an additional layer of safety, helping to prevent the accidental injection of medication into the bloodstream, which is a known risk of the procedure.

Bottom Line

Investor optimism for Milestone Scientific is growing as the company demonstrates a clear trend of rising revenue and improving operational discipline on its path to profitability.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.